40
Participants
Start Date
June 30, 2006
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
Cetuximab
The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
UPMC Cancer Center -Beaver, Beaver
UPMC Cancer Center - Clairton, Clairton
UPMC Cancer Center -Wexford, Wexford
UPMC Cancer Center -Sewickley Medical Center, Moon Township
UPMC Cancer Center -McKeesport, McKeesport
UPMC Cancer Center -Haymaker Rd., Monroeville
UPMC Cancer Center -Mosside Blvd., Monroeville
UPMC Presbyterian -Radiation Oncology, Pittsburgh
UPMC Cancer Center -Delafield Rd., Pittsburgh
UPMC Cancer Center -St. Margaret, Pittsburgh
Universtity of Pittsburgh Cancer Institute -Hillman Cancer Center, Pittsburgh
UPMC Cancer Center -UPMC Shadyside, Pittsburgh
UPMC Cancer Center -Passavant, Pittsburgh
UPMC Cancer Center -Drake, Pittsburgh
UPMC Cancer Center -St. Clair, Pittsburgh
UPMC Cancer Center -Washington, Washington
UPMC Cancer Center -Robert Eberly Pavilion, Uniontown
UPMC Cancer Center -Uniontown, Uniontown
UPMC Cancer Center - Oakbrook Commons, Greensburg
UPMC Cancer Center -Arnold Palmer Pavilion, Greensburg
UPMC Cancer Center -Mt. Pleasant, Mount Pleasant
UPMC Cancer Center -Indiana, Indiana
UPMC Cancer Center -John P. Murtha Pavilion, Johnstown
UPMC Cancer Center -Jameson, New Castle
UPMC Cancer Center -New Castle, New Castle
UPMC Cancer Center -UPMC Northwest, Seneca
Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center, Hershey
Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Emory Winship Cancer Institute, Atlanta
Sylvester Comprehensive Cancer Center, University of Miami, Miami
UPMC Cancer Center -Teramana Cancer Center, Steubenville
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of Pittsburgh
OTHER